Literature DB >> 9692823

Identification of CD56 and CD57 by flow cytometry in Ewing's sarcoma or primitive neuroectodermal tumor.

L J Gardner1, J M Polski, R Fallon, C H Dunphy.   

Abstract

CD56 and CD57 are commonly considered as natural killer and neuroectodermal markers, but their expression has been identified in a wide spectrum of neoplasms including some cases of Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET). We report two cases of small, round blue cell tumor (SRBCT), in which flow cytometry immunophenotyping (FCI) detected strong expression of CD56 and CD57 (one case). Immunohistochemical staining with Leu-19 and Leu-7 confirmed the FI results. Although CD56 and CD57 expression is consistent with ES/PNET, it can be potentially misleading if results of FCI are interpreted in the absence of other findings. These cases suggest the utility of FCI in undifferentiated SRBCT. The literature on CD56 and CD57 expression in ES/PNET is reviewed and discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9692823     DOI: 10.1007/s004280050213

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  6 in total

1.  Histological heterogeneity of Ewing's sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support.

Authors:  Antonio Llombart-Bosch; Isidro Machado; Samuel Navarro; Franco Bertoni; Patrizia Bacchini; Marco Alberghini; Apollon Karzeladze; Nikita Savelov; Semyon Petrov; Isabel Alvarado-Cabrero; Doina Mihaila; Philippe Terrier; Jose Antonio Lopez-Guerrero; Piero Picci
Journal:  Virchows Arch       Date:  2009-10-17       Impact factor: 4.064

2.  CD99-positive large cell neuroendocrine carcinoma with rearranged EWSR1 gene in an infant: a case of prognostically favorable tumor.

Authors:  Vicki S Malone; Sheila M Dobin; Kathleen A Jones; Ludvik R Donner
Journal:  Virchows Arch       Date:  2010-07-09       Impact factor: 4.064

3.  Detection of the CD56+/CD45- immunophenotype by flow cytometry in neuroendocrine malignancies.

Authors:  G J Bryson; D Lear; R Williamson; R C W Wong
Journal:  J Clin Pathol       Date:  2002-07       Impact factor: 3.411

4.  Assessment of minimal residual disease in ewing sarcoma.

Authors:  Lars M Wagner; Teresa A Smolarek; Janos Sumegi; Daniel Marmer
Journal:  Sarcoma       Date:  2012-03-12

Review 5.  A narrative review of central nervous system involvement in acute leukemias.

Authors:  Dalma Deak; Nicolae Gorcea-Andronic; Valentina Sas; Patric Teodorescu; Catalin Constantinescu; Sabina Iluta; Sergiu Pasca; Ionut Hotea; Cristina Turcas; Vlad Moisoiu; Alina-Andreea Zimta; Simona Galdean; Jakob Steinheber; Ioana Rus; Sebastian Rauch; Cedric Richlitzki; Raluca Munteanu; Ancuta Jurj; Bobe Petrushev; Cristina Selicean; Mirela Marian; Olga Soritau; Alexandra Andries; Andrei Roman; Delia Dima; Alina Tanase; Olafur Sigurjonsson; Ciprian Tomuleasa
Journal:  Ann Transl Med       Date:  2021-01

6.  Contribution of multiparameter flow cytometry immunophenotyping to the diagnostic screening and classification of pediatric cancer.

Authors:  Cristiane S Ferreira-Facio; Cristiane Milito; Vitor Botafogo; Marcela Fontana; Leandro S Thiago; Elen Oliveira; Ariovaldo S da Rocha-Filho; Fernando Werneck; Danielle N Forny; Samuel Dekermacher; Ana Paula de Azambuja; Sima Esther Ferman; Paulo Antônio Silvestre de Faria; Marcelo G P Land; Alberto Orfao; Elaine S Costa
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.